checkAd

     596  0 Kommentare MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application For Guselkumab in Europe - Seite 2


    Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

    HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.


    This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

     

    For more information, please contact:
    MorphoSys AG
    Anke Linnartz
    Head of Corporate Communications & IR

    Jochen Orlowski
    Associate Director Corporate Communications & IR

    Alexandra Goller
    Senior Manager Corporate Communications & IR

    Tel: +49 (0) 89 / 899 27-404
    investors@morphosys.com





    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: MorphoSys AG via Globenewswire

    --- End of Message ---

    MorphoSys AG
    Lena-Christ-Str. 48 Martinsried / Munich Germany

    WKN: 663200;ISIN: DE0006632003;Index:TECH All Share,CDAX,Prime All Share,TecDAX,HDAX,MIDCAP;
    Listed: Freiverkehr in Börse Stuttgart,
    Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
    Freiverkehr in Börse Berlin,
    Freiverkehr in Börse Düsseldorf,
    Freiverkehr in Bayerische Börse München,
    Freiverkehr in Niedersächsische Börse zu Hannover,
    Prime Standard in Frankfurter Wertpapierbörse,
    Regulierter Markt in Frankfurter Wertpapierbörse;


    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application For Guselkumab in Europe - Seite 2 MorphoSys AG / MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application For Guselkumab in Europe . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content …

    Schreibe Deinen Kommentar

    Disclaimer